Bolette Hartmann

Bolette Hartmann serves as an Associate Professor at the Department of Biomedical Sciences (BMI) within the Faculty of Health and Medical Sciences at the University of Copenhagen. With 25 years of specialized experience in gut hormones and bone metabolism, she maintains an active research profile with over 340 publications to her name. Her laboratory is based at Blegdamsvej 3B, 2200 København N, and she can be contacted via email at bhartmann@sund.ku.dk or by phone at +4535327501, +4523264411.

Professor Hartmann's research primarily focuses on the intricate relationship between gut hormones and bone metabolism, with particular expertise in incretin hormones including GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Her work spans multiple disciplines including endocrinology, metabolism, diabetes research, and bone physiology. The research group investigates how these gut-derived hormones influence bone turnover, glucose metabolism, and various other physiological processes, with implications for treating metabolic disorders and bone diseases.

Her extensive publication record demonstrates consistent research productivity, with numerous high-impact articles published in 2025 covering topics from receptor pharmacology to clinical applications. The research output shows strong collaboration with colleagues at the University of Copenhagen, particularly with Professor Jens Juul Holst, and extends to international partnerships. Her work has been disseminated through various channels including journal articles, conference abstracts, book chapters, and patents.

Professor Hartmann is also the co-founder of Bainan Biotech, a spinout company established based on years of research exploring the connection between gut hormones and bone turnover conducted at the University of Copenhagen. The Department of Biomedical Sciences and Bainan Biotech maintain an active collaboration on research projects aimed at generating new knowledge for the prevention and treatment of bone-related diseases. This academic-industry partnership exemplifies the translational nature of her research program, bridging basic science discoveries with potential therapeutic applications.